GLP-1 Therapy and Its Impact on Cardiometabolic Health

Explore GLP-1 therapy to improve cardiometabolic health and effectively manage chronic conditions in the body.

Abstract

In this educational post, I walk you through how modern glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 incretin therapies fit into a risk-centered care pathway for type 2 diabetes (T2D), obesity, atherosclerotic cardiovascular disease (ASCVD), heart failure, and chronic kidney disease (CKD)—far beyond glucose control alone. I synthesize the latest findings from leading researchers using rigorous, evidence-based methods and connect them with my real-world clinical observations in integrative chiropractic and functional medicine practice. I explain the physiology of the incretin system, the glucose-dependent pharmacology behind A1C and weight reduction, and the comparative efficacy across dulaglutide, semaglutide, and tirzepatide. I also detail cardiovascular and renal outcomes, practical titration protocols, peri-procedural guidance, and when to de-intensify basal insulin in favor of postprandial control. Finally, I show how integrative chiropractic care—including neuromusculoskeletal optimization, autonomic regulation, pain reduction, and lifestyle scaffolding—enhances the efficacy, tolerability, and long-term adherence of GLP-1–based therapy.

Why GLP-1–Centered Care Has Transformed Modern Metabolic Medicine

As a clinician working at the intersection of metabolic medicine, neuromusculoskeletal health, and lifestyle therapeutics, I have witnessed a profound shift in how we treat T2D and metabolic syndrome. The older glucose-only approach has ceded ground to a risk-based, organ-protective strategy that prioritizes preventing ASCVD events, heart failure, and CKD progression, while also lowering glucose and facilitating durable weight loss (American Diabetes Association [ADA], 2024, 2025).

• The modern care model emphasizes:

• • Aggressive blood pressure, lipid, and glycemic control
  • Clinically meaningful weight reduction and fitness progression
  • Tobacco cessation and appropriate antiplatelet therapy
  • Early use of organ-protective agents (GLP-1 RAs and SGLT2 inhibitors) when ASCVD or CKD risk is present, regardless of baseline A1C or metformin use (ADA, 2024, 2025; KDIGO, 2024)

In my integrative practice, pairing GLP-1/GIP therapies with structured neuromusculoskeletal care improves adherence to movement prescriptions, reduces sedentary behavior, and modulates autonomic tone—changes that directly influence glycemic variability, blood pressure, and inflammatory status. This integration has consistently yielded fewer gastrointestinal (GI) discontinuations and better quality-of-life outcomes, a pattern I discuss across my clinical insights at chiropracticscientist.com and on my professional profile (see links at the end).

The Incretin System: Physiological Foundations That Drive Outcomes

To understand why GLP-1–based care is different, we need to start with the incretin effect—the amplified insulin response when glucose is ingested orally versus intravenously (Nauck & Meier, 2018). In T2D, this effect is blunted: endogenous GLP-1 secretion is reduced, and GIP insulinotropic activity is impaired.

• Key physiological actions of GLP-1/GIP therapies:
  • Pancreas:

• Glucose-dependent insulin secretion via beta-cell GLP-1 receptor activation—minimizing hypoglycemia when not combined with insulin or sulfonylureas
• Suppression of glucagon during hyperglycemia reduces inappropriate hepatic glucose output

• • Gut and brain:

• Slowed gastric emptying to blunt postprandial surges
• Central satiety signaling that lowers caloric intake and reduces hedonic food drive (van Bloemendaal et al., 2014)

• • Adipose and weight:

• Energy intake reduction plus possible adipocyte signaling effects support clinically significant weight loss, improving insulin sensitivity and blood pressure (Müller et al., 2019)

• • Cardiovascular and renal systems:

• MACE reductions across several GLP-1 RA trials (Marso et al., 2016; Gerstein et al., 2019)
• Renal benefits, including lower albuminuria and slower eGFR decline (Mann et al., 2017; FLOW Investigators, 2024)

Why these mechanisms matter clinically:

• Glucose-dependent action confers safety and synergy with SGLT2 inhibitors, thereby minimizing the risk of hypoglycemia (ADA, 2024, 2025).
• Postprandial control complements basal insulin and often enables de-intensification of insulin therapy.
• Weight loss improves multiple risk domains—glycemia, blood pressure, lipids, OSA burden, and inflammatory tone.

From Glucose-Centric to Risk-Centric: Guideline Alignment and What It Means Day-to-Day

Large multicenter trials have reshaped guideline recommendations:

• The ADA Standards of Care (2024, 2025) recommend GLP-1 RAs with cardiovascular benefit and SGLT2 inhibitors for patients with T2D and ASCVD, heart failure, or CKD, regardless of A1C or metformin use (ADA, 2024, 2025).
• KDIGO (2024) endorses SGLT2 inhibitors to slow CKD progression and supports GLP-1 RAs for added glycemic and renal protection, particularly in albuminuric patients or when SGLT2i are contraindicated.
• ACC/AHA guidance frames comprehensive cardiometabolic risk-lowering, including weight reduction as a disease-modifying intervention.

In practice, this means we prioritize risk reduction first and then track glucose improvements as part of a broader risk portfolio. When ASCVD or CKD risk is present, GLP-1 RAs become frontline therapy—often alongside SGLT2 inhibitors—even before intensifying insulin.

Comparative Efficacy: Dulaglutide, Semaglutide, Tirzepatide, and Class Nuances

Different incretin agents yield different magnitudes of glycemic and weight change, with important trial-proven distinctions:

• Dulaglutide: Weekly dosing, meaningful A1C reduction and weight loss; demonstrated MACE reduction in REWIND, including strong primary prevention representation (Gerstein et al., 2019).
• Semaglutide (subcutaneous and oral):

• • Robust A1C lowering and weight loss, with MACE reduction in SUSTAIN-6 and microvascular signals (Marso et al., 2016).
  • Kidney-protective evidence recently strengthened with FLOW (FLOW Investigators, 2024).
  • Higher-dose weight-management formulation (2.4 mg) reduced MACE by 20% in non-diabetic patients with established ASCVD (SELECT Investigators, 2023).
  • Improved symptoms and functional capacity in obesity-related HFpEF (Kosiborod et al., 2023).

• Tirzepatide (dual GIP/GLP-1): Superior A1C and weight reductions vs semaglutide in head-to-head trials (Frías et al., 2021; Jastreboff et al., 2022), with ongoing CV outcomes work.

Practical pharmacology:

• Potency and titration: More potent agents require conservative titration, as acute gastric emptying effects and satiety changes can intensify GI symptoms early.
• Label differences: Cardiovascular and renal labels are not uniform; match agent choice to a patient’s risk profile, tolerability, and coverage.

My clinical lens: When satiety signals are weak or weight loss plateaus, transitioning to higher-potency incretin therapy (e.g., semaglutide up-titration or tirzepatide initiation) can unlock better appetite control and risk-factor improvement—provided titration remains patient-centered and GI-aware (Frías et al., 2021; Wilding et al., 2021).

---

Balancing Body and Metabolism- Video

---

Case Pattern: Over-Basalization, Postprandial Hyperglycemia, and Why GLP-1 Often Comes Before Prandial Insulin

A common scenario I see in the clinic:

• A 66-year-old woman with 12+ years of T2D
• A1C 8.3%, fasting 140–160 mg/dL, bedtime/postprandial 160–170 mg/dL
• On metformin 1000 mg BID, statin, ARB, SGLT2 inhibitor, and insulin degludec 66 units daily
• BMI 32.5 kg/m2

Clinical reasoning:

• She is likely over-basalized. A practical threshold is often near 5 U/kg/day when fasting is near target, but A1C remains elevated—suggesting postprandial excursions drive overall hyperglycemia. At ~100 kg, 66 units/day (~0.66 U/kg) points to diminishing returns with further basal intensification.
• Problem focus: Postprandial hyperglycemia and weight gain at higher insulin doses.
• Strategic pivot: Introduce a GLP-1 RA (or dual GLP-1/GIP) to target postprandial surges, promote weight loss, and enable basal de-escalation—often preferred before adding prandial insulin (ADA, 2024).

Why GLP-1 before prandial insulin:

• Targets postprandial glucose via gastric emptying and insulinotropic effects
• Reduces hypoglycemia risk compared to prandial insulin
• Facilitates weight loss instead of the weight gain typically seen with insulin intensification
• Aligns with CV/renal protection when agents carry outcomes data

Practical Protocols: Initiation, Titration, and Basal Insulin De-Intensification

When I initiate GLP-1/GIP therapy, I follow a stepwise, patient-centered protocol:

• Baseline labs and metrics:

• • A1C, fasting lipids, CMP, eGFR, urine ACR, and blood pressure

• Maintain synergistic therapies:

• • Continue metformin (if tolerated) and SGLT2 inhibitor for cardio-renal synergy (ADA, 2024; KDIGO, 2024)

• Start a GLP-1 RA (example: semaglutide SC weekly):

• • Begin at 25 mg weekly for 4 weeks, then 0.5 mg, advancing to 1.0 mg as tolerated; consider higher doses per labeling and goals

• Adjust basal insulin:

• • If fasting runs 90–120 mg/dL, reduce basal by 10–20% at initiation to mitigate hypoglycemia; reassess weekly
  • Avoid aggressive basal increases; prioritize postprandial control and weight trajectory

• GI tolerability coaching:

• • Encourage small, protein-forward meals, avoid large high-fat loads during titration, maintain hydration, and escalate doses slowly
  • Consider simple supports (ginger tea, mindful meal pacing, fiber timing) and, when needed, short-course antiemetics per clinician guidance

Outcome targets:

• Glycemic:

• • Fasting 90–130 mg/dL, 2-hour postprandial generally <180 mg/dL, individualized A1C goals (<7% or <6.5% if safe)

• Cardiometabolic:

• • LDL-C <70 mg/dL in ASCVD, BP <130/80 mmHg in high-risk patients, and reduced albuminuria

• Weight:

• • Anticipate 3–5% loss over 3–6 months with GLP-1 RA and lifestyle synergy, larger reductions with tirzepatide or higher-dose semaglutide

My clinic tip: I pause dose escalation once patients report a stable satiety signal and steady weight loss without undue GI symptoms. More medication is not always more beneficial. The right dose is the one that sustains behavior change.

How Integrative Chiropractic Care Amplifies GLP-1 Therapy

In my integrative practice, neuromusculoskeletal optimization and autonomic regulation are essential companions to incretin therapy. These hands-on and movement-centered strategies improve adherence, reduce pain, and support appetite regulation and sleep—key determinants of metabolic success.

• Neuromusculoskeletal optimization:

• • Spinal manipulation and myofascial techniques reduce pain and improve mobility, enabling patients to meet activity prescriptions
  • Improved gait mechanics and core stability reduce joint stress and perceived exertion, supporting sustainable exercise and better insulin sensitivity
  • Reduced nociceptive input attenuates sympathetic overdrive, lowering catecholamine-related insulin resistance and BP variability

• Autonomic regulation and vagal tone:

• • Postural and breathing strategies, thoracic mobilization, and diaphragmatic work support vagal afferent signaling, complementing GLP-1’s gut–brain axis effects on satiety and gastric motility
  • Heart rate variability (HRV)–guided biofeedback improves stress resilience, glycemic stability, and sleep quality

• Pain, sleep, and appetite:

• • Chronic pain heightens cortisol and disrupts sleep, driving hyperphagia and glycemic variability; multimodal pain care reduces sedating meds and restores circadian regularity

• Functional nutrition and meal patterning:

• • GLP-1 therapy pairs best with protein-rich, fiber-forward meals and resistance training to preserve lean mass during weight loss
  • Meal timing is structured to harmonize with gastric emptying changes and prevent reactive hypoglycemia during titration

• Care coordination:

• • Ongoing communication across primary care, endocrinology, cardiology/renal, and integrative teams ensures coherent titration, surveillance for gallbladder/pancreatitis risk, and timely lipid/BP adjustments as weight falls

Clinical observations: Across my practice platforms, I consistently see that early chiropractic intervention reduces GI discontinuations. At the same time, progressive mobility and strength programs preserve lean mass—a critical factor for metabolic durability (see chiropracticscientist.com and LinkedIn profile linked below).

Mechanisms Behind Weight, Blood Pressure, and Kidney Gains

• Weight loss and adipose signaling:

• • GLP-1 RAs reduce hunger through hypothalamic satiety pathways and modulate reward circuits, lowering high-calorie food salience
  • Adipose loss reduces leptin resistance and pro-inflammatory cytokines, improving insulin sensitivity

• Blood pressure reduction:

• • Weight loss, SGLT2-linked natriuresis, and improved autonomic balance lower BP
  • Data suggest endothelial function improvements, better nitric oxide bioavailability, and reduced vascular inflammation (Ceriello et al., 2013)

• Renal protection:

• • Downstream effects include reduced albuminuria, improved glomerular hemodynamics, and slower eGFR decline; semaglutide’s FLOW trial strengthens kidney-protective claims (FLOW Investigators, 2024)

Managing Adverse Effects and Special Considerations

Most side effects are manageable with anticipatory guidance and slow titration:

• GI symptoms:

• • Nausea, early satiety, constipation, or diarrhea often occur initially; they typically resolve within 2–8 weeks with meal adjustments and patience (Rubino et al., 2022)

• Gallbladder:

• • Rapid weight loss can increase gallstone risk; counsel on hydration, moderate dietary fat, and prompt evaluation for biliary pain (Kechagias et al., 2022)

• Pancreatitis:

• • Rare; avoid in active pancreatitis and educate on severe abdominal pain with emesis (Dicembrini et al., 2019)

• Thyroid C-cell warning:

• • Boxed warning applies to long-acting GLP-1 RAs; avoid in MEN2 or personal/family history of MTC (FDA/EMA labeling)

• Renal events:

• • Volume depletion from vomiting can precipitate AKI; teach sick-day rules and hydration

• Peri-procedural aspiration risk:

• • Retained gastric contents are more likely early in therapy or in high-risk GI profiles; coordinate with anesthesia to hold weekly agents 1–2 weeks pre-procedure when indicated (American Society of Anesthesiologists, 2023)

• Retinal and neuropsychiatric signals:

• • Rapid glucose improvement may transiently worsen diabetic retinopathy; maintain eye screening (Marso et al., 2016)
  • Mixed signals on mood; proactively screen and support mental health

When and How to Switch: Dulaglutide to Semaglutide or Tirzepatide

Patients often ask about switching when satiety feels inadequate or when weight loss plateaus:

• Optimize current agent:

• • Consider dulaglutide escalation to 0–4.5 mg weekly if tolerated and appropriate

• Switch to semaglutide:

• • After the last dulaglutide dose, start semaglutide 5 mg weekly for ~4 weeks, then advance to 1.0 mg if satiety remains inadequate; hold longer at 0.5 mg in GI-sensitive profiles

• Switch to tirzepatide:

• • After the last dulaglutide dose, wait 1 week, then begin tirzepatide at 5 mg weekly, titrating to 5–15 mg based on tolerability and satiety response (Frías et al., 2021; Jastreboff et al., 2022)

Why this works:

• Pharmacodynamics: Higher GLP-1 receptor potency (semaglutide) or dual incretin signaling (tirzepatide) amplifies satiety and postprandial control
• GI tolerance: Lower starting doses allow neurogastrointestinal adaptation to gastric emptying changes
• Patient-centered dosing: Aligning titration to goals and tolerability improves adherence and behavior change

My practice habit: I escalate only until the satiety threshold is reliably achieved; then I consolidate with lifestyle scaffolding to preserve lean mass and reinforce daily movement.

Clinical Vignette: Tammy, Age 58 — Reframing Therapy for Plateaus

• Medications: maximal metformin, dulaglutide 1.5 mg weekly, dapagliflozin daily
• Challenges: A1C 8.1, BMI 38; minimal fullness, only 5 lb loss; no GI issues

Clinical reasoning:

• Her primary barriers are inadequate satiety and plateaued weight; a more potent incretin strategy aligns better with multi-outcome goals
• Options:

• • Switch to semaglutide with stepwise titration to 1.0–2.0 mg weekly, as available, or initiate tirzepatide, titrating every 4 weeks
  • Reserve basal insulin addition for persistent fasting hyperglycemia despite optimized incretin therapy
  • Reinforce integrative plan: resistance training 2–3 days/week, protein distribution (25–35 g per meal), fiber targets (25–35 g/day), HRV-guided stress modulation, sleep hygiene

Outcome goals:

• A1C toward? 7.0 within 3–6 months
• 7–10% body weight reduction at 6 months, recognizing dual agonist potential for greater reductions
• Improved satiety and fewer postprandial excursions

Why each step:

• Higher-potency incretin enhances central satiety and gastric slowing, tackling inadequate fullness
• Slow titration protects adherence by reducing GI symptoms
• Maintaining SGLT2 therapy sustains kidney and heart failure benefits
• Reserving insulin reduces the risk of weight gain
• Integrative movement and stress work protect lean mass and improve insulin sensitivity

Future Directions: Next-Generation Incretins and Expanding Indications

• Semaglutide SELECT: Secondary CV prevention benefit in non-diabetic ASCVD (SELECT Investigators, 2023)
• Semaglutide FLOW: Kidney protection with early separation of event curves (FLOW Investigators, 2024)
• Tirzepatide CV outcomes: Ongoing trials will clarify its ASCVD role relative to semaglutide’s data
• Oral small-molecule GLP-1s (e.g., forglipron): Phase 2 signals for weight and glycemia (Gantz et al., 2024)
• Triple agonists (GLP-1/GIP/glucagon): Early-phase data suggest greater thermogenesis and fat mass reduction (Sgarbi et al., 2023)
• MASH/NASH: Semaglutide shows histologic improvements in steatohepatitis; fibrosis effects vary (Newsome et al., 2021; Armstrong et al., 2022)
• HFpEF with obesity: Semaglutide improves symptoms and function (Kosiborod et al., 2023)

These advances support tailoring therapy to phenotype: obesity-dominant, nephropathy risk, ASCVD history, or hepatic steatosis—each potentially favoring different incretin strategies or co-agonist combinations.

A Practical Roadmap: From Initiation to Maintenance, With Chiropractic Integration

Phase 1: Onboarding and baseline

• Define goals: weight, waist circumference, activity minutes, sleep metrics, mood/craving scales
• Select the agent based on comorbidities, preference, and coverage
• Start low, go slow: Establish a titration calendar and GI comfort plan
• Chiropractic focus: Gentle mobilization, diaphragmatic breathing, and low-load stabilization to ease initiation

Phase 2: Titration and behavior anchoring (weeks 4–16)

• Advance doses carefully; pause escalation once satiety stabilizes
• Nutrition: Whole-food protein, fiber-rich vegetables, and balanced low-glycemic carbohydrates
• Movement: Progress from walking to strength and interval conditioning as joints allow
• Monitor mental health; maintain open dialogue around mood changes

Phase 3: Consolidation and long-term maintenance (beyond week 16)

• Identify the minimal maintenance dose that sustains appetite control
• Chiropractic care shifts to performance: spinal stability, gait efficiency, movement quality
• Relapse planning: Protein-first breakfast, daily step minimums, sleep consistency
• Follow-ups taper while aligning with medication refills and life events

Cost, Access, and Real-World Constraints

Affordability and coverage can be limiting. I work with patients to:

• Maximize insurance utility using CV and CKD indications when present
• Navigate step therapy (e.g., dulaglutide escalation before newer agents)
• Leverage lifestyle strategies to achieve the lowest effective dose

Adherence strategies that help:

• Clear titration calendars and written GI comfort plans
• Early constipation management with fiber, hydration, magnesium when appropriate, and progressive mobility
• Scheduling hands-on care 2–3 days post-injection for sensitive patients to avoid peak GI overlap

Closing Perspective: Precision Pharmacology Meets Hands-On, Movement-Centered Care

The contemporary standard recognizes GLP-1–based therapy as a cornerstone for patients with T2D and elevated cardiometabolic or renal risk. When embedded in a coordinated, integrative chiropractic and functional medicine framework, these therapies deliver more than numbers on a chart—they translate into fewer cardiovascular events, slower progression of kidney disease, meaningful weight loss, better sleep, reduced pain, and improved daily function.

In practice, the synergy is clear: precision pharmacology opens a window for improved energy, appetite control, and cardio-renal protection; integrative chiropractic care turns that window into a durable doorway to lasting habits and risk reduction. The most consistent success stories arise when physiology-informed dosing and whole-person movement care proceed in lockstep.

Explore my clinical observations and ongoing updates:

• Clinical insights: https://chiropracticscientist.com/
• Professional profile: https://www.linkedin.com/in/dralexjimenez/

References

• American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care. https://diabetesjournals.org/care
• American Diabetes Association. (2025). Standards of medical care in diabetes—2025. Diabetes Care. https://diabetesjournals.org/care
• American Society of Anesthesiologists. (2023). Guidelines on perioperative management of GLP-1 receptor agonists. https://www.asahq.org
• Armstrong, M. J., Gaunt, P., Aithal, G. P., et al. (2022). Semaglutide in patients with NASH: A randomized, controlled trial. The Lancet. https://www.thelancet.com
• Ceriello, A., Esposito, K., Testa, R., et al. (2013). GLP-1 reduces endothelial dysfunction, inflammation, and oxidative stress in diabetes. Diabetes Care. https://diabetesjournals.org/care/article/36/8/2346/38384
• DeFronzo, R. A. (2009). From the triumvirate to the ominous octet. Diabetes. https://diabetesjournals.org/diabetes/article/58/4/773/13919
• Dicembrini, I., Montereggi, C., Nreu, B., et al. (2019). Pancreatitis risk with GLP-1 RAs and DPP-4 inhibitors: Meta-analysis. Diabetes Research and Clinical Practice. https://www.sciencedirect.com/science/article/abs/pii/S0168822719301802
• FLOW Investigators. (2024). Semaglutide and kidney outcomes in T2D and CKD. The Lancet. https://www.thelancet.com
• Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide vs. semaglutide once-weekly in T2D. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
• Gantz, I., Chen, M., & Suryawanshi, S. (2024). Oral GLP-1 receptor agonists in development. Nature Reviews Drug Discovery. https://www.nature.com/nrd/
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., et al. (2019). Dulaglutide and cardiovascular outcomes in T2D (REWIND). The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext
• Husain, M., Birkenfeld, A. L., Donsmark, M., et al. (2019). Oral semaglutide and cardiovascular outcomes (PIONEER 6). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1901118
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
• (2024). Clinical practice guideline for the management of CKD in diabetes. Kidney International. https://kdigo.org
• Kechagias, S., et al. (2022). Gallstone risk and rapid weight loss: Clinical considerations. Obesity Reviews. https://onlinelibrary.wiley.com
• Kosiborod, M., et al. (2023). Semaglutide in obesity-related HFpEF. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2303712
• Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., et al. (2017). Liraglutide and renal outcomes in T2D. New England Journal of Medicine. https://www.nejm.org
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and cardiovascular outcomes (LEADER). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1603827
• Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and cardiovascular outcomes (SUSTAIN-6). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
• Müller, T. D., Finan, B., Bloom, S. R., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. https://www.sciencedirect.com/science/article/pii/S2212877819301013
• Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity, and Metabolism. https://onlinelibrary.wiley.com/doi/full/10.1111/dom.13129
• Newsome, P. N., et al. (2021). Semaglutide for NASH: Randomized, placebo-controlled trial. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2028395
• Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Weight loss maintenance with semaglutide. JAMA. https://jamanetwork.com/journals/jama/article-abstract/2777887
• Rubino, D., et al. (2022). Managing GI events with GLP-1 receptor agonists. Diabetes, Obesity, and Metabolism. https://onlinelibrary.wiley.com
• SELECT Investigators. (2023). Semaglutide and cardiovascular outcomes in overweight/obesity with established CVD, no diabetes. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2307561
• van Bloemendaal, L., IJzerman, R. G., Ten Kulve, J. S., et al. (2014). GLP-1 receptor activation modulates appetite- and reward-related brain areas. Diabetes Care. https://diabetesjournals.org/care/article/37/9/2470/38137
• Wiviott, S. D., Raz, I., Bonaca, M. P., et al. (2019). Dapagliflozin and cardiovascular outcomes in T2D (DECLARE-TIMI 58). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1812389
• Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in T2D (EMPA-REG OUTCOME). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1504720 —

SEO tags: GLP-1 receptor agonist, GIP agonist, tirzepatide, semaglutide, dulaglutide, incretin effect, gastric emptying, satiety, weight loss, A1C reduction, cardiovascular outcomes, MACE reduction, renal protection, CKD, FLOW trial, SELECT trial, HFpEF, ADA 2024 guidelines, ADA 2025 guidelines, KDIGO 2024, SGLT2 inhibitor, postprandial hyperglycemia, insulin de-intensification, integrative chiropractic care, autonomic regulation, neuromusculoskeletal optimization, resistance training, functional medicine, appetite regulation, peri-procedural guidance, GI tolerability, obesity medicine, metabolic syndrome, cardiometabolic risk